SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Por:
Majem, M, Juan, O, Insa, A, Reguart, N, Trigo, JM, Carcereny, E, Garcia-Campelo, R, Garcia, Y, Guirado, M, Provencio, M
Publicada:
1 ene 2019
Resumen:
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.
Filiaciones:
Majem, M:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
Juan, O:
Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain
Insa, A:
Hosp Clin Univ Valencia, Med Oncol Dept, Valencia, Spain
Reguart, N:
Univ Barcelona, IDIBAPS, Hosp Clin, Med Oncol Dept, Barcelona, Spain
Trigo, JM:
Hosp Univ Virgen Victoria, Med Oncol Dept, Malaga, Spain
Carcereny, E:
Badalona Hosp Germans Trias i Pujol, Inst Catala Oncol, Badalona, Spain
Garcia-Campelo, R:
Complexo Hosp Univ A Coruna, Med Oncol Dept, La Coruna, Spain
Garcia, Y:
Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Med Oncol Dept, Sabadell, Spain
Guirado, M:
Hosp Gen Univ Elche, Med Oncol Dept, Elche, Spain
Provencio, M:
Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Madrid, Spain
Hybrid Gold, Green Published
|